Chonluten (EDL): experimental lung-inflammation peptide
A lab-studied synthetic three-piece peptide that may calm lung inflammation by dialing down inflammatory signals; not an approved drug, sold as a supplement in Russia.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Synthetic tripeptide bioregulator (Khavinson program)
Evidence tier: In vitro / assay evidence
Status: Not approved by FDA, EMA, MHRA, Health Canada, or TGA for any therapeutic indication; sold in Russia as an oral functional-food/dietary supplement
Best-supported effect: TNF production inhibition and IL-6 suppression in LPS-stimulated THP-1 monocyte cell-line studies (in vitro); LAT1 transporter affinity supported by molecular docking
Main caveat: No monotherapy clinical trials exist; the only human-context reports use Chonluten in combination with Bronchogen, making peptide-specific attribution impossible; independent Western replication of all claims is absent
What this is
Chonluten is a synthetic tripeptide (Glu-Asp-Gly, also designated EDG or T-34) developed within Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the Cytogen series — short peptides designed to mirror the regulatory sequences of specific tissue types — and is directed at bronchial mucosa and lung epithelium. Within the Khavinson framework, Chonluten is distinguished from Bronchogen (AEDL, a tetrapeptide targeting deeper lung epithelial differentiation): Chonluten is positioned for stress-protective and anti-inflammatory gene regulation in bronchial mucosa. The published evidence base is small and concentrated within a single research orbit; no controlled clinical trials establishing monotherapy efficacy have been conducted or indexed in Western databases.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Anecdotal / combination-only | Observational clinical reports describe Chonluten used alongside Bronchogen in chronic bronchitis with asthmatic component and in physical-performance assessments under low-oxygen conditions; peptide-specific attribution is impossible because no monotherapy data exist; no RCTs indexed in Western databases |
| Animal | None identified | No dedicated in vivo animal studies are identifieds available literature |
| In vitro | Moderate | TNF production inhibition in LPS-stimulated THP-1 monocytes; IL-6 suppression; reduced monocyte adhesion to activated endothelial cells; modulation of stress-response gene expression (c-Fos, HSP70), antioxidant enzyme genes (SOD), and inflammatory mediator genes (COX-2, TNF-alpha) |
| Computational | Present | Molecular docking supports LAT1 amino acid transporter affinity (ICM-Score: −30.30); provides a proposed cellular uptake mechanism |
| Mechanism | Plausible | Proposed transcriptional modulation of stress-response and anti-inflammatory gene programs in bronchial epithelium via DNA-regulatory interaction; direct DNA interaction by a tripeptide remains contested; in vitro evidence supports the anti-inflammatory signaling component; no independent replication outside the Khavinson group |
Replication caveat: All published evidence originates from one research network (Khavinson program, St. Petersburg). No independent Western respiratory-immunology laboratory has replicated the in vitro TNF/IL-6 suppression results or the gene-regulation claims. The clinical literature is Russian-language, uncontrolled, and involves combination therapy only. Confidence in any claim derived from this evidence base must reflect the absence of independent replication.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Anti-inflammatory activity in bronchial/immune cell models | Supported (in vitro) | In vitro | Medium — peer-reviewed cell-line studies; no in vivo or human translation established; no independent replication outside Khavinson group |
| LAT1 transporter-mediated cellular uptake | Supported (computational prediction) | Computational | Low — molecular docking only; in vivo transporter validation absent |
| Effective adjunct for chronic bronchitis or COPD | Not established | Human | Low — all clinical reports are combination use (Chonluten + Bronchogen); no monotherapy data; no RCTs; no independent Western replication; peptide-specific attribution impossible |
| Equivalent to or interchangeable with Bronchogen | Contradicted / not supported | None | High — published literature explicitly distinguishes Chonluten (EDG, bronchial mucosa stress/inflammation) from Bronchogen (AEDL, deeper lung epithelial differentiation); different sequences and proposed tissue targets |
| Systemic anti-inflammatory benefit via oral or sublingual route | Not established | None | High confidence in verdict — oral/sublingual bioavailability to lung tissue is uncharacterized in humans; route-equivalence claim unsupported |
| Safe for long-term use in inflammatory lung disease | Not established | None | High confidence in verdict — no chronic exposure or long-term toxicology data in any system |
Assay conditions
This section reports conditions used in the in vitro studies and computational work identified in the available literature. It does not establish animal or human exposure.
| Context | System | Assay condition | Timepoint | Endpoint | Limitation |
|---|---|---|---|---|---|
| In vitro cell-line study | THP-1 human monocyte/macrophage cell line; LPS-stimulated | EDG tripeptide applied at study-reported concentration; exact concentration not individually extracted | End-of-assay measurement | TNF production inhibition; IL-6 suppression; monocyte adhesion to activated endothelium | Cell-line models do not predict clinical anti-inflammatory effect at achievable in vivo concentrations; no bronchoalveolar lavage or pulmonary biomarker data in humans |
| In vitro gene-expression study | Bronchial epithelial cell model (Khavinson group) | EDG tripeptide; exact concentration and protocol not individually extracted | End-of-assay measurement | Expression of c-Fos, HSP70, SOD, COX-2, TNF-alpha regulatory genes | Results not replicated outside originating laboratory |
| Computational docking | LAT1 amino acid transporter model | Molecular docking simulation | Not applicable | LAT1 binding affinity; ICM-Score −30.30 | Docking score does not confirm in vivo transporter activity or cellular uptake in lung tissue |
Assay limitations
- All in vitro evidence is generated within the Khavinson research orbit; no independent Western laboratory has replicated the TNF/IL-6 suppression or gene-regulation findings.
- Cell-line experiments in THP-1 monocytes are mechanistically informative but routinely fail to predict clinical anti-inflammatory benefit at achievable in vivo concentrations.
- The proposed mechanism of direct DNA interaction by a short tripeptide is contested in the broader scientific community; the in vitro evidence does not resolve this debate.
- LAT1 transporter affinity is supported by molecular docking only; in vivo transporter validation in lung tissue has not been performed.
- Oral, sublingual, and parenteral bioavailability of the EDG tripeptide in humans is uncharacterized; resistance to intestinal degradation is not equivalent to quantified systemic exposure to lung tissue.
- No human pharmacokinetic, dose-escalation, or formal toxicology studies meeting Western regulatory standards are identifieds available literature.
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved | Not approved for any indication; not recognized as a dietary supplement ingredient; not on the FDA compounding-eligible peptide list; available only via personal import of Russian-market product or research-chemical channels, neither of which is an authorized clinical pathway |
| EU (EMA) | Not authorized | Not authorized as a medicine by EMA, MHRA, TGA, or Health Canada per available literature |
| Russia | Sold as functional food / dietary supplement | Available under the Khavinson Peptides / Peptides.ru brand as oral capsules and sublingual drops; positioned as a dietary supplement or functional food, not as a registered prescription medicine; per available sources; not independently verified in this card |
| WADA | Unclear — treat injectable form as potentially prohibited | Not specifically named on the WADA Prohibited List per source; because no governmental health authority approves Chonluten for human therapeutic use, injectable Chonluten can reasonably be read as falling under the WADA S0 catch-all category; status is per available sources and has not been independently refreshed in this card |
Mechanism
Chonluten (Glu-Asp-Gly) is proposed to enter bronchial epithelial and immune cells via the LAT1 amino acid transporter — a mechanism supported by molecular docking (ICM-Score: −30.30) but not validated in vivo. Once intracellular, the tripeptide is proposed to interact with DNA regulatory regions, modulating gene programs involved in stress defense and inflammation. In vitro studies from the Khavinson group report modulation of stress-response genes (c-Fos, HSP70), antioxidant enzyme genes (SOD), and inflammatory-mediator genes (COX-2, TNF-alpha) in bronchial epithelial cell models. In THP-1 monocyte/macrophage experiments, the EDG sequence inhibited TNF production in LPS-stimulated cells and acted as a natural inducer of TNF tolerance, while also suppressing IL-6 expression and reducing monocyte adhesion to activated endothelial cells.
The proposed mechanism of direct DNA interaction by a short tripeptide is contested in the broader scientific community; the sequence length raises questions about specificity and nuclear access. Independent replication of any mechanistic claim in Western respiratory-immunology laboratories has not occurred. Mechanistic evidence from cell-line systems does not establish clinical anti-inflammatory benefit in the lung.
Chemistry
| Field | Value |
|---|---|
| Sequence | Glu-Asp-Gly (EDG) |
| Length | 3 amino acids |
| Topology | Linear |
| Alternative designations | T-34 (some Khavinson-group publications); EDL (source title — likely typographic variant; body text consistently uses EDG) |
| Molecular weight | Not individually extracted from source |
| Formula | Not individually extracted from source |
| Modifications | None described in source |
| Sequence confidence | Needs review — source title uses "EDL" while body text consistently uses "EDG"; minor source-level designation discrepancy |
Open questions
- Independent replication of in vitro findings: The TNF/IL-6 suppression and gene-regulation findings have been generated exclusively within the Khavinson research orbit. External validation by Western respiratory-immunology laboratories is the most important gap before any clinical translation can be considered.
- Peptide-specific clinical evidence: All available human-context reports use Chonluten in combination with Bronchogen. Monotherapy efficacy data — even within the Russian clinical framework — do not exist. Without these, Chonluten's individual contribution cannot be established.
- Human pharmacokinetics: Oral, sublingual, and parenteral bioavailability of the EDG tripeptide in humans is uncharacterized. The LAT1 transporter hypothesis has not been validated in vivo in any species.
- DNA-interaction mechanism: The proposed direct interaction of a tripeptide with DNA regulatory regions remains mechanistically contested. Specificity, nuclear access, and the pathway from uptake to gene regulation have not been demonstrated outside Khavinson-group publications.
- Long-term safety: Chronic anti-inflammatory gene modulation in respiratory epithelium has not been studied for off-target effects. No dose-escalation, formal toxicology, or long-term exposure studies meeting Western regulatory standards are available.
- Comparative efficacy: No head-to-head studies against first-line respiratory pharmacotherapy (inhaled corticosteroids, LABA/LAMA combinations, biologics) exist.
- Route bioavailability equivalence: The claim that oral or sublingual absorption produces systemic exposure comparable to injection has not been measured in humans; tripeptide resistance to intestinal degradation is not equivalent to quantified lung-tissue delivery.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does Chonluten naturally concentrate in lung tissue because a particular protein channel that bronchial cells use to absorb nutrients also happens to grab this peptide?
If Chonluten uses a real, identifiable transporter to enter bronchial cells, its distribution could be predicted and controlled. This would make it possible to design improved versions that reach inflamed lung tissue more reliably, potentially helping patients with chronic bronchitis or early COPD.
Does the single amino acid difference between Chonluten and its close relative Ovagen determine whether the peptide can touch cell membranes, or whether it stays in the water around cells?
Understanding this one-residue rule would let chemists rationally design better versions of the entire Khavinson peptide family. Instead of testing dozens of variants, researchers could predict which version will work for a given target tissue based on one simple chemical property.
Would delivering this lung-targeting peptide directly to the colon work better for bowel inflammation than taking it by mouth for the lungs?
Treatments for inflammatory bowel disease are expensive and carry serious risks. If a very simple, cheap peptide suppresses the key inflammatory signal in the gut when delivered locally, it could become an affordable option for millions of people who cannot access or tolerate biological drugs.
▸3-letter notation
▸citationbibtex
@peptide{pep10942,
sequence = {EDL},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}